Sign In
Buy IFRX
$1.70
-0.0200 (-1.16%)
At Close: Jul 31, 2026
InflaRx Showcases Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting
08:00am, Friday, 07'th Mar 2025
JENA, Germany, March 07, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced
InflaRx to Showcase Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting
09:00am, Friday, 28'th Feb 2025
JENA, Germany, Feb. 28, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced
InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences
07:30am, Tuesday, 25'th Feb 2025
JENA, Germany, Feb. 25, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced
InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
04:01pm, Tuesday, 18'th Feb 2025
JENA, Germany, Feb. 18, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system,
InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
09:45pm, Thursday, 13'th Feb 2025
JENA, Germany, Feb. 13, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system,
InflaRx Announces Public Offering of Ordinary Shares and Pre-Funded Warrants
04:01pm, Thursday, 13'th Feb 2025
JENA, Germany, Feb. 13, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system,
InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference
07:30am, Thursday, 23'rd Jan 2025
JENA, Germany, Jan. 23, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced
InflaRx Stock Rises 8% on Conditional EC Nod for COVID-19 Drug
11:50am, Thursday, 16'th Jan 2025
IFRX stock gains 8% on EC nod for Gohibic, under exceptional circumstances, to treat adult patients with COVID-19-induced ARDS.
JENA, Germany, Jan. 15, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced
InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904
07:30am, Friday, 20'th Dec 2024
JENA, Germany, Dec. 20, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced
JENA, Germany, Nov. 15, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced
InflaRx N.V. (IFRX) Reports Q3 Loss, Tops Revenue Estimates
09:40am, Friday, 08'th Nov 2024
InflaRx N.V. (IFRX) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.27.
InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update
07:30am, Friday, 08'th Nov 2024
JENA, Germany, Nov. 08, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced
JENA, Germany, Sept. 25, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced
3 Penny Stocks To Buy With Just $750
10:36am, Tuesday, 24'th Sep 2024
Anyone with any experience as an investor knows that while penny stocks can produce strong returns, they're also risky.
